PersonaDx provides a clinically validated biomarker test that combines molecular genetic profiling with patient clinical data to assess metastatic risk in colorectal cancer patients. The AI‑driven risk score categorizes patients, helping oncologists choose effective therapies, avoid unnecessary treatment, and improve outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Metastatic colorectal cancer (mCRC) leads to the majority of cancer deaths, yet clinicians lack a reliable, individualized tool to predict which patients will develop metastasis and to tailor treatment accordingly.
Solution
PersonaDx offers a clinically validated biomarker test that combines molecular genetic profiling with patient clinical data to generate a precise metastatic risk assessment for mCRC patients. The test leverages data-driven algorithms to stratify patients into distinct risk categories, enabling oncologists to select therapies that are most likely to be effective while avoiding unnecessary treatments. By providing clear prognostic information, the test supports evidence‑based decision making, reduces treatment costs, and aims to improve survival outcomes and quality of life.
Target Audience
Primary customers are oncologists and oncology care teams treating patients with colorectal cancer, as well as cancer centers and precision‑medicine networks seeking validated prognostic tools.
Features
- Molecular genetics panel that detects key genomic alterations associated with metastatic potential
- Integrated clinical data model that incorporates patient history, tumor stage, and laboratory values
- AI‑enhanced risk scoring algorithm that produces quantitative metastatic risk categories
- Clinically validated performance metrics demonstrating high prognostic accuracy for mCRC
- Report format that aligns with standard oncology workflows and can be incorporated into electronic health records